GMT

Versius customer reach increases as CMR Surgical closes 2023 with strongest quarter on record

Retrieved on: 
Thursday, January 4, 2024
General surgery, Urology, CMR, Elective surgery, Software, Medtech, Surgeon, Hospital, GMT, CMR Surgical, Patient, Acceleration

CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces a strong close to 2023.

Key Points: 
  • CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces a strong close to 2023.
  • The Versius Surgical Robotic System is being used to perform benign and complex surgical procedures around the world, including low anterior resections, prostatectomies, lobectomies and hysterectomies.
  • Additionally, the launch of new advanced technologies for Versius – across both hardware and software – will be a gamechanger this year.
  • If you wish to see more, please contact CMR Surgical at:

Versius customer reach increases as CMR Surgical closes 2023 with strongest quarter on record

Retrieved on: 
Thursday, January 4, 2024
General surgery, Urology, CMR, Elective surgery, Software, Medtech, Surgeon, Hospital, GMT, CMR Surgical, Patient, Acceleration

CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces a strong close to 2023.

Key Points: 
  • CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces a strong close to 2023.
  • The Versius Surgical Robotic System is being used to perform benign and complex surgical procedures around the world, including low anterior resections, prostatectomies, lobectomies and hysterectomies.
  • Additionally, the launch of new advanced technologies for Versius – across both hardware and software – will be a gamechanger this year.
  • If you wish to see more, please contact CMR Surgical at:

EQS-News: MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study 

Retrieved on: 
Saturday, December 30, 2023
Spleen, Patient, EST, Food, TNF, Survival, Constipation, Bone marrow, BET, Prognosis, Diarrhea, Plasma, Anemia, Fatigue, Headache, Disease, Nausea, GMT, Ruxolitinib, Thrombocytopenia, Weakness, Dizziness, ASH, JAK, MorphoSys, COVID-19, Periodic breathing, European Medicines Agency, IL-6, PST, Development, Fibrosis, Cough, Dysgeusia, FACP

Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.

Key Points: 
  • Average hemoglobin levels were greater in patients receiving pelabresib and ruxolitinib than in those receiving placebo plus ruxolitinib, starting at week 9 and continuing to week 24.
  • Increased cytokine levels are associated with all four disease hallmarks; increased IL-8 levels are also associated with worse survival outcomes.
  • Discontinuation rates due to adverse events were 10.7% with pelabresib and ruxolitinib and 6.5% with placebo plus ruxolitinib.
  • “The four hallmarks of myelofibrosis – enlarged spleen, anemia, bone marrow fibrosis and disease-associated symptoms – have a strong impact on a patient’s life.

PurMinds Chief Innovation Officer to Speak at the Analytical Cannabis Educational Webinar about Next Generation Psychedelics and the Neurobiology of Neuroplastogens

Retrieved on: 
Wednesday, November 29, 2023
Trauma, Neuroplasticity, Depression, Psychiatry, Brain, GMT, Anxiety, PTSD, Neuroscience, The Company, Neurology, Pharmaceutical industry

This webinar will explore the intersection of neuroscience and psychedelics, highlighting their potential therapeutic benefits for mental health conditions such as depression, anxiety, PTSD, and addiction.

Key Points: 
  • This webinar will explore the intersection of neuroscience and psychedelics, highlighting their potential therapeutic benefits for mental health conditions such as depression, anxiety, PTSD, and addiction.
  • Dr. Reichelt will delve into the neurobiology of psychedelics, emphasizing their role in promoting neuroplasticity, which allows for the rewiring of the brain.
  • Ongoing clinical research will also be discussed, including the use of these substances in controlled settings to address trauma, reduce symptoms, and tackle substance dependence.
  • Finally, Dr. Reichelt will explore next-generation psychedelics without hallucinatory effects and the potential of psychedelics as innovative therapeutic tools in psychiatry and neurology.

ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data

Retrieved on: 
Wednesday, December 13, 2023
Quality of life, UPS, Neoplasm, Tumor microenvironment, Male, IMC, Heterotrimeric G protein, FAP, AIM, Cancer, GMT, Toxicity, Enzyme, Doxorubicin, Patient, Safety, Medical imaging

Cohort 7, the final cohort in the three-weekly dose escalation safety study of AVA6000, has completed enrolment and is ongoing

Key Points: 
  • Cohort 7, the final cohort in the three-weekly dose escalation safety study of AVA6000, has completed enrolment and is ongoing
    Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to provide detailed pre-clinical, clinical and pharmacokinetic data from the Phase 1a dose escalation study of its lead pre|CISIONTM programme, AVA6000, a tumour activated form of doxorubicin.
  • The key conclusions drawn from the data for AVA6000 to date are:
    The pre|CISIONTM platform targets the release of a chemotherapy to the tumour as intended.
  • A maximum tolerated dose has not been reached in the three-weekly dose escalation study despite dosing approximately 3.5x the normal level of doxorubicin in the highest and final dose cohort in this part of the Phase 1a study.
  • Given the favourable safety data from the three-weekly dosing study, a fortnightly dosing study, which is now screening patients with high FAP levels in the United States, will assist in optimising the schedule and dose for a potentially pivotal Phase 2 study in 2024.

Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer

Retrieved on: 
Monday, December 11, 2023
Marketing, CMR, Johnson & Johnson, Medtech, Medical device, Surgeon, Hospital, GMT, CMR Surgical, Smith & Nephew, Smith, Emerging market, Growth, Patient, Pharma, Nursing

CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer.

Key Points: 
  • CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer.
  • The appointment comes as CMR accelerates its already successful installations of Versius, bringing minimal access surgery to more patients around the world.
  • Massimiliano joins CMR from Evercare Group, a leading hospital group, where he served as Group Chief Executive Officer and Board member.
  • Having led a large hospital group, the momentum and need for surgical robotics is only growing, both to bring more equity of care for patients, and to look after our surgical workforce.

Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer

Retrieved on: 
Monday, December 11, 2023
Marketing, CMR, Johnson & Johnson, Medtech, Medical device, Surgeon, Hospital, GMT, CMR Surgical, Smith & Nephew, Smith, Emerging market, Growth, Patient, Pharma, Nursing

CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer.

Key Points: 
  • CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer.
  • The appointment comes as CMR accelerates its already successful installations of Versius, bringing minimal access surgery to more patients around the world.
  • Massimiliano joins CMR from Evercare Group, a leading hospital group, where he served as Group Chief Executive Officer and Board member.
  • Having led a large hospital group, the momentum and need for surgical robotics is only growing, both to bring more equity of care for patients, and to look after our surgical workforce.

CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

Retrieved on: 
Thursday, December 21, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, SRR, RNA, ASX, Partnership, Multimedia, Messenger, Vaccine, Arcturus Therapeutics, Therapy, Vaccination, GMT, Omicron, CSL, ARCT, Patient, Arcturus, Safety, Senior

ARCT-154 results were achieved with one sixth the dose of Comirnaty® (5 μg vs 30 μg).

Key Points: 
  • ARCT-154 results were achieved with one sixth the dose of Comirnaty® (5 μg vs 30 μg).
  • The study was conducted in partnership with Meiji Seika Pharma, a global health company based in Japan.
  • The primary objective was to demonstrate immunological non-inferiority of ARCT-154 to Comirnaty®, as measured by neutralizing antibodies against Wuhan-Hu-1 SARS-CoV-2.
  • Key secondary objectives included the assessment of immunological non-inferiority and superiority against the Omicron BA.4/5 subvariant and vaccine tolerability assessed using participant-completed electronic diaries.

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

Retrieved on: 
Thursday, December 21, 2023
SRR, RNA, Senior, ASX, Partnership, Messenger, Vaccine, Arcturus Therapeutics, SAN, Therapy, Vaccination, GMT, Omicron, CSL, COVID-19, Doctor of Philosophy, Upendra J. Chivukula, Patient, Arcturus, Safety

KING OF PRUSSIA, Pa. and SAN DIEGO, Dec. 21, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA (sa-mRNA) vaccine, elicited a numerically higher immune response (meeting the non-inferiority criteria) against the original Wuhan-Hu-1 virus strain,  and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty®. ARCT-154 results were achieved with one-sixth the dose of Comirnaty® (5 μg vs 30 μg).

Key Points: 
  • Both vaccines were well-tolerated, with no causally associated severe or serious adverse events.
  • The study was conducted in partnership with Meiji Seika Pharma, a global health company based in Japan.
  • "This study represents the first phase of CSL and Arcturus' plans to launch this innovative vaccine platform globally."
  • Key secondary objectives included the assessment of immunological non-inferiority and superiority against the Omicron BA.4/5 subvariant and vaccine tolerability assessed using participant-completed electronic diaries.

Genel Energy PLC: Update on Tawke PSC

Retrieved on: 
Tuesday, December 26, 2023
DNO, GMT, Kurdistan Region, DNO ASA, IMC, Security (finance)

Genel Energy plc (‘Genel’ or ‘the Company’) notes that DNO ASA, as operator of the Tawke PSC (Genel 25% working interest), has today issued an update on licence activity.

Key Points: 
  • Genel Energy plc (‘Genel’ or ‘the Company’) notes that DNO ASA, as operator of the Tawke PSC (Genel 25% working interest), has today issued an update on licence activity.
  • The Tawke field was reopened on 18 July, and gross production from the Tawke licence in Q3 2023 totalled 25,984 bopd.
  • Genel will issue its trading and operations update in respect of the third quarter of 2023 next Tuesday, 14 November 2023.
  • Genel will host a live presentation on the Investor Meet Company (‘IMC’) platform on the day at 1000 GMT.